Shire gains more of Avexa in apricitabine rejig
This article was originally published in Scrip
Executive Summary
Shire Pharmaceuticalswill increase its ownership of Avexato over 11% because of a modification of the terms of its original licensing agreement with the Australian firm for the HIV antiviral apricitabine.